Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV-16/18 AS04 vaccine alternative versus standard 3-dose schedule in healthy young women
2007-003256-11Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2007
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine in human papillomavirus infection (2 arms), sponsored by GSK. Primary endpoints: Anti-HPV-16 seroconversion rate one month after third dose, Anti-HPV-18 seroconversion rate one month after third dose and 2 more. Started Nov 2007; status: completed.
02
Drugs
Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2007-003256-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003256-11.